

**CERTIFICATION FORM:
EPIPEN® (epinephrine injection, USP) Auto-Injector
for EPIPEN4SCHOOLS® Replenishment Offer**

VIATRIS™ will replenish your school's supply of EPIPEN (epinephrine injection, USP) or EPIPEN JR® (epinephrine injection, USP) Auto-Injectors prior to your annual eligibility date at no additional cost, provided that your school used the EPIPEN or EPIPEN JR Auto-Injectors or authorized generic for EPIPEN or EPIPEN JR Auto-Injectors for EPIPEN4SCHOOLS free product to treat a life-threatening allergic reaction (anaphylaxis) in your school.

First, please complete all of the fields below.

School Name/District Name:
School Address:
City/State/Zip:
School Phone:
School Contact Name:
School Contact Email:
What was the date of the anaphylactic event? MM/DD/YYYY
<p>Where did the anaphylactic event occur?</p> <ul style="list-style-type: none"> • Classroom • Cafeteria • Playground • Gym • Other _____
<p>What was the suspected cause of the anaphylactic event?</p> <ul style="list-style-type: none"> • Food • Insect Sting/Bite • Latex • Medication • Other _____
<p>Did the person who experienced anaphylaxis have a known life-threatening allergy?</p> <ul style="list-style-type: none"> • Yes • No • Unknown
<p>Was the person who experienced anaphylaxis a:</p> <ul style="list-style-type: none"> • Student • Staff member • Visitor • Other _____
<p>Which epinephrine auto-injector was administered to treat the anaphylactic event?</p> <ul style="list-style-type: none"> • Authorized generic for EPIPEN Auto-Injector • Authorized generic for EPIPEN JR Auto-Injector • EPIPEN Auto-Injector • EPIPEN JR Auto-Injector
<p>Was more than one EPIPEN or EPIPEN JR Auto-Injector or authorized generic for EPIPEN or EPIPEN JR Auto-Injector administered to treat the anaphylactic event?</p> <ul style="list-style-type: none"> • Yes • No
<p>Was 911 or emergency medical services called?</p> <ul style="list-style-type: none"> • Yes • No • Unknown
<p>Did the person who experienced anaphylaxis receive emergency medical care?</p> <ul style="list-style-type: none"> • Yes • No • Unknown

<p>Who administered the EPIPEN or EPIPEN JR Auto-Injector or authorized generic for EPIPEN or EPIPEN JR Auto-Injector to the person experiencing anaphylaxis (please do not name people directly)?</p> <ul style="list-style-type: none"> • School Nurse • Student other than one experiencing the event • Staff member • Visitor • Self-Administered
<p>Was the person who experienced anaphylaxis taken to the hospital?</p> <ul style="list-style-type: none"> • Yes • No • Unknown
<p>Is epinephrine your school's first-line treatment when an anaphylactic reaction occurs?</p> <ul style="list-style-type: none"> • Yes • No • Unknown

I confirm that the EPIPEN or EPIPEN JR Auto-Injector or authorized generic for EPIPEN or EPIPEN JR Auto-Injector used in the anaphylactic event described above was received through the *EPIPEN4SCHOOLS* program.

I certify that the information above is true and accurate.

Signature:

Date:

Indications (the following information applies to both EPIPEN and its Authorized Generic)

EPIPEN and EPIPEN JR Auto-Injectors are indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis to stinging insects (e.g., order Hymenoptera, which include bees, wasps, hornets, yellow jackets and fire ants) and biting insects (e.g., triatoma, mosquitoes), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g., radiocontrast media) and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. EPIPEN and EPIPEN JR Auto-Injectors are intended for immediate administration in patients who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions.

Important Safety Information (the following information applies to both EPIPEN and its Authorized Generic)

EPIPEN (epinephrine injection, USP) 0.3 mg and EPIPEN JR (epinephrine injection, USP) 0.15 mg Auto-Injectors are intended for immediate administration as emergency supportive therapy only and are not intended as a substitute for immediate medical or hospital care. **In conjunction with the administration of epinephrine, the patient should seek immediate medical or hospital care.** More than two sequential doses of epinephrine should only be administered under direct medical supervision.

EPIPEN and EPIPEN JR should **only** be injected into the anterolateral aspect of the thigh. **Do not inject intravenously, into buttock, or into digits, hands, or feet.** Instruct caregivers to hold the leg of young children firmly in place and limit movement prior to and during injection to minimize risk of injection-related injury.

Rare cases of serious skin and soft tissue infections have been reported following epinephrine injection. Advise patients to seek medical care if they develop symptoms of infection such as persistent redness, warmth, swelling, or tenderness at the injection site.

Epinephrine should be used with caution in patients with heart disease, and in patients who are on drugs that may sensitize the heart to arrhythmias, because it may precipitate or aggravate angina pectoris and produce ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation, have been reported, particularly in patients with underlying cardiac disease or taking cardiac glycosides, diuretics, or anti-arrhythmics.

Patients with certain medical conditions or who take certain medications for allergies, depression, thyroid disorders, diabetes, and hypertension, may be at greater risk for adverse reactions. Common adverse reactions to epinephrine include anxiety, apprehensiveness, restlessness, tremor, weakness, dizziness, sweating, palpitations, pallor, nausea and vomiting, headache, and/or respiratory difficulties.

Please see the [Full Prescribing Information](#) for EPIPEN

Please see the [Full Prescribing Information](#) for the Authorized Generic for EPIPEN

EPIPEN, EPIPEN JR, EPIPEN4SCHOOLS are registered trademarks of Mylan Inc., a Viatris Company.

VIATRIS is a trademark of Mylan Inc., a Viatris Company.

© 2021 Viatris Inc. All Rights Reserved. EPI-2021-0501